Can a blister beetle extract banish common warts? phase 3 trial investigates
NCT ID NCT07637734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the active treatment or a vehicle control. The main goal is to see if YCANTH can completely clear all treatable warts by day 84, with a secondary focus on sustained clearance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YCANTH (cantharidin topical solution)
What this could lead to
If successful, this could provide a proven, safe topical treatment for common warts, potentially clearing them without invasive procedures.
What could go wrong
This is a Phase 3 trial, but results may not apply to all wart types or locations. Some people may not respond, and side effects like blistering or pain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS (HPV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DelRicht Research
Overland Park, Kansas, 66209, United States
-
DelRicht Research
Baton Rouge, Louisiana, 70809, United States